Lv1
70 积分 2025-07-07 加入
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
1个月前
已完结
MabSelect VH3 Protein A affinity resin effectively separates antibody species containing different numbers of VH3 domain and shows improved aggregate separation capability
1个月前
已完结
Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation
1个月前
已完结
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
2个月前
已完结
Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse
2个月前
已完结
Trends and challenges in bispecific antibody production
2个月前
已完结
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study
3个月前
已完结
Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game
3个月前
已完结
Immunophenotypic Pattern of Myeloid Populations by Flow Cytometry Analysis
3个月前
已完结
CD38 as a Novel Immunosuppressive Target in Prostate Cancer
3个月前
已完结
皖公网安备34019202002308
